International Regulatory Peptide Society

Missions

Admin Octavo — 2008-05-20T14:58:04Z

The International Regulatory Peptide Society promotes scientific meetings and exchanges devoted to all aspects of basic and clinical research on regulatory peptides and related topics thus keeping up the tradition of the International Symposia on Gut Hormones and Regulatory Peptides - Missions

Statutes

Admin Octavo — 2008-05-20T09:17:21Z

Article I: Name

An association is hereby constituted, named "The International Regulatory Peptide Society” according to the French law of July 1901 and the provisions of this constitution.

Article II: Aims

"The International Regulatory Peptide Society” is a non-profit making organisation with the following aims:

to promote scientific meetings devoted to all aspects of basic and clinical research on regulatory peptides and related topics thus keeping up the great tradition of the International Symposia on Gut Hormones (see article X “The International Symposium on Regulatory Peptides”)
to establish Viktor Mutt lectureship and award and eventually other awards
to distribute scholarships and promote postgraduate education
to establish contacts and links with other organisations and institutions sharing close goals
to disseminate information about "The International Regulatory Peptide Society” activities
to collect funds in order to fulfil its scientific and social purposes

Article III: Headquarters

The headquarters of the association is housed in France at the work place of the chairman of the Steering Committee (address: Inserm, 1 Avenue Jean Poulhès, BP84225, 31432 Toulouse Cedex 4). This registered office may be transferred to another location by decision of the Steering Committee.

Article IV: Duration

The association is established for an unlimited period of time.

Article V: Membership

Membership of the association is open to any person holding a PhD and/or MD graduated having an interest in regulatory peptides and related scientific subjects. Members will pay a contribution, the amount of which is proposed by the Steering Committee and approved by the general assembly. Participants to the biennial scientific meeting, “The International Symposium on Regulatory Peptides” will pay their contribution through a registration fee to the symposium. Any member may withdraw from the association at any time. The membership terminates automatically in the case of non-payment of the contribution.

Article VI: Central Fund

There is a Central Fund composed of membership fees, grants provided by public institutions, sponsor companies and any other sources permitted by the law. The fund must be strictly used to fulfil the aims of the association as defined in article II “aims”. No payment from the Central Fund shall be made to any member of the association except for the reimbursement of expenditure incurred on behalf of the Society and approved by the Steering Committee.

Article VII: Responsibilities of the Steering Committee

The governing body of the association is the Steering Committee. It is composed of 9-12 members approved by the general assembly. The Steering Committee has members of different nationalities and of different scientific fields to represent the international vocation of the association. Each member will serve a term of 6 years which may in exception be renewed for one additional period. In the event of an unexpected vacancy, the Steering Committee will nominate a substitute but this substitution will require ratification by the General Assembly. The Steering Committee elects a President (chairman) and a Treasurer. The President chairs meetings of the Steering Committee. He is responsible for writing minutes of Steering Committee and General Assembly meetings and any business report related to the activities of the association except financial reports. In the event of his absence, the President may nominate any Steering Committee member as his deputy, inheriting the same authority as he.

The Treasurer is entrusted with the funds of the association, their collection, their safe keeping, and disbursement according to decisions of the Steering Committee. The budget and annual accounts are prepared by the Treasurer. They are presented to the Steering Committee and to the General Assembly for approval according to the law of July 1st, 1901. The Treasurer has the authority to sign individual transactions according to rules defined by the Steering Committee.

The Steering Committee writes guidelines concerning the biennial scientific meeting of the association (The International Symposium on Regulatory Peptides) and sub-committees of the association.

Article VIII: Steering Committee meetings

The Steering Committee meets at least once a year and is convened by the President. Agenda of the meetings and any proposal, nomination or document to be discussed is circulated by the president to members of the committee at least fifteen days beforehand through electronic mail. Decisions of the committee are valid only if at least 50% of the members are present or represented. A member of the committee may be represented by another member who may hold one written proxy. Decisions are made by simple majority of the members present or represented. In the event of an equally divided vote, the vote of the President is decisive. Persons who are not members of the Steering Committee may attend meetings of the committee by invitation but cannot vote. Minutes of meetings are written by the President and circulated to all members of the Steering Committee within a period of two weeks for approval using electronic mail.

Article IX: General Assembly

The General Assembly of the association is the highest body of the association. It consists of members of the association. It meets at least every two years and is convened by the President. The General Assembly makes decisions on the election of members to the Steering Committee, reports on activities of the association, the budget, the annual accounts, the venue for scientific meetings (The International Symposium on Regulatory Peptides), alteration of the statutes, co-operation with other associations and societies, dissolution of the association and any business which falls into the scope of the association. Votes of the General Assembly are valid only if at least 50% of the members are present. Decisions of the General Assembly are made by a simple majority of participants. Minutes of the General Assembly are written and signed by the President and the Treasurer of the association and are circulated to all members within fifteen days.

Article X: Dissolution

The association and it's statutes may be dissolved at any time at a meeting of the General Assembly at which at least two-thirds of the members vote in favour of dissolution. Prior notification of the proposal for dissolution should be made to the Steering Committee at least 6 months beforehand. In the event of the dissolution of the association, the Steering Committee is responsible for the liquidation of the association. The remaining fund would be distributed for future use exclusively for the same goals as those defined in article II of the current statutes.

Article XI: Sub-committees/European Section

The Steering Committee may appoint sub-committees to undertake specific tasks designated by the Steering Committee. Sub-committees are subject to guidelines defined by the Steering Committee. A committee for the selection of the recipient of Viktor Mutt lectureship is appointed by the International Steering Committee. The Viktor Mutt lectureship has been established in recognition of the fundamental research of Viktor Mutt in the field of gastrointestinal peptide hormones and neuropeptides. It is awarded every two years at the time of the International Symposium on Regulatory Peptides. The Steering Committee forms a scientific advisory committee. Members of the Scientific Advisory Committee attend to (or watch over) the international influence of the association and pay special attention to the fact that the association covers all fields of regulatory peptide research. They actively contribute to establish connections with disseminate groups of scientific investigators or individuals working on regulatory peptides and related subjects and they assist the Steering Committee and organisers of the International Symposium on Regulatory Peptides in adequately establishing the scientific programme of the symposium.
The European section of the International Regulatory Peptide Society has the aims of the International Society in the European area.

Article XII: The International Symposium on Regulatory Peptides

The official scientific meeting of the association is “The International Symposium on Regulatory Peptides”. First held in 1976, the International Symposium on Gastrointestinal Hormones has expanded its scope in recognition of the role of gut peptides outside the digestive tract. In 1996, the meeting was renamed as the “International Symposium on Regulatory Peptides”. The organisation of this biennial scientific meeting is delegated to a member of the association at the venue selected by the General Assembly. This member forms and chairs a local organising committee subject to guidelines prepared by the Steering Committee. The local organising committee has the responsibility of symposium organisation in co-operation with the Steering Committee and sub-committees of the association.

Article XIII

For everything not explicitly covered by these articles, the law of July 1st 1901 and the usages on international associations shall remain applicable.

Scientific Advisory Board

Admin Octavo — 2008-05-20T09:13:31Z

Ardil Joy, Belfast, UK
Audigier Yves, Toulouse, France
Bado André, Paris, France
Baldwin Graham, Melbourne, Australia
Beglinger Christoph, Basel, Switzerland
Bloom Steeve, London, UK
Chow Billy KC, Hong Kong, China
Date Yukari, Miyazaki, Japan
Deacon Carolyn, Copenhagen, Denmark
Delgado Mario, Granada, Spain
Depoortere Inge, Brussels, Belgium
Dockray Graham, Liverpool, UK
Drucker Daniel, Toronto, Canada
Eipper Betty, Connecticut, USA
Florio Tullio, Genova, Italy
Fourmy Daniel, Toulouse, France
Fournier Alain, Laval, Québec
Giraud Audy, Melbourne, Australia
Hilsted Linda, Copenhagen, Denmark
Hokfelt Thomas, Stockholm, Sweeden
Holst Jens, Copenhagen, Denmark
Holzer Peter, Graz, Austria
Kieffer Timothy, Vancouver, Canada
Kopin Alan, Boston, USA
Langer Ingrid, Brussels, Belgium
Leiter Andrew, Boston, USA
Lindsberg Iris, Baltimore, USA
Malagon Maria, Cordoba, Spain
Mazella Jean, Nice, France
Merchand Juanita, Ann Arbor, USA
Pisegna Joseph, Los Angeles, USA
Rehefeld Jens, Copenhagen, Denmark
Reubi Jean-Claude, Berne, Switzerland
Rozengurt Enrique, Los Angeles, USA
Schmidt Wolfgang, Bochum, Germany
Seong Jae Young, Seoul, Korea
Shioda Seiji, Tokyo, Japan
Shulkes Arthur, Melbourne, Australia
Steiner Donald, Chicago, USA
Sugano Kentaro, Tochigi, Japan
Taché Yvette, Los Angeles, USA
Tourwé Dirk, Brussels, Belgium
Varro Andrea, Liverpool, UK
Vaudry Hubert, Rouen, France
Waldum Heldge, Trondheim, Norway
Wang Timothy, New York, USA
Wierup Nils, Lund, Sweden
Wolfe Michael, Boston, USA

Steering Committee

Admin Octavo — 2008-05-20T09:12:29Z

Daniel Fourmy, PhD (Chair)
Inserm U858 - I2MR,
Toulouse, France
daniel.fourmy@inserm.fr

Christoph Beglinger, MD, PhD (Treasurer)
Division of Gastroenterology, University Hospital,
Basel, Switzerland
beglinger@tmr.ch

Graham Baldwin, PhD
Department of Surgery, University of Melbourne, Austin Health,
Melbourne, Victoria, Australia
grahamsb@unimelb.edu.au

Dan Drucker, MD, PhD
Mount Sinai Hospital, Samuel Lunenfeld Research Institute,
Toronto, Ontario, Canada
d.drucker@utoronto.ca

Linda Hilsted, MD, PhD
University Department of Clinical Biochemistry, Rigshospitalet,
Copenhagen, Denmark
linda.hilsted@rh.regionh.dk

Wolfgang E. Schmidt, MD, PhD
Department of Gastroenterology and Hepatology, St. Josef-Hospital, Ruhr-University Bochum School of Medicine,
Bochum, Germany
wolfgang.e.schmidt@ruhr-uni-bochum.de

Kentaro Sugano, MD, PhD
Department of Internal Medicine, Division of Gastroenterology, Jichi Medical University,
Tochigi, Japan
sugano@jichi.ac.jp

Andrea Varro, MD, PhD
Physiological Laboratory, School of Biomedical Sciences, University of Liverpool,
Liverpool, UK
A.Varro@liverpool.ac.uk

Yvette Taché, PhD
Department of Medicine, UCLA,
Los Angeles, CA , USA
ytache@mednet.ucla.edu

Seiji Shioda, MD, PhD,
Department of Anatomy I, Showa University, School of Medicine,
Tokyo, Japan
shioda@med.showa-u.ac.jp

Michael Wolfe, MD
Section of Gastroenterology, Boston Medical Center, Boston University _ School of Medicine,
Boston, MA, USA
Michael.Wolfe@bmc.org

John Walsh

Admin Octavo — 2008-05-20T09:04:26Z

- History

Werner Creutzfeldt

Admin Octavo — 2008-05-20T09:03:57Z

The field of gastrointestinal Endocrinology has gained widespread attention over the last decades, as the importance of gut hormones in the regulation of glucose homeostasis, gastrointestinal functions and energy homeostasis has now become more and more evident. One of the fathers of this concept was Professor Werner Creutzfeldt, whose landmark research contributions pioneered this field for the past 50 years. His foresighted research activities have led to the detailed investigation of the incretin effect, i.e. the augmentation of insulin secretion by gut hormones, which has now been accepted as a key mechanism for postprandial glucose control. On August 30th, 2006, Werner Creutzfeldt passed away after a long and heroic struggle against a series of chronic illnesses. Perhaps as small solace, he could see the emerging fruits of his long-standing and visionary research one year prior to his death, when the first member of the new drug class of incretin mimetics was launched for the treatment of type 2 diabetes, which of certain would not have been available at this time without the invaluable contributions made by him personally and the Goettingen research group.

Werner Creutzfeldt was born on May 11th, 1924 in Kiel,Germany and attended Medical School at the Universities of Freiburg, Kiel, and Tübingen. In his early research projects carried out at the University of Freiburg, where he worked as a resident and later as a senior consultant, he provided a detailed description of the morphology and function of the islets of Langerhans and their abnormalities in various experimental models of diabetes. These studies still impress with their detailedness, accuracy and innovative methodology. In subsequent research projects, Werner Creutzfeldt examined the morphological and biochemical features of neuroendocrine tumours, the pharmacokinetics and pharmacodynamics of oral antidiabetic agents and the pathophysiology of “post-transfusion” hepatitis. These contributions soon became classic landmarks in the field. In 1964, Werner Creutzfeldt was appointed as full professor and chairman of the Department of Medicine at the University of Göttingen, where he soon formed one of the most recognized groups in the fields of Gastroenterology and Endocrinology, from which numerous highly successful scientists emerged, many of which have subsequently taken over leading academic positions in Internal Medicine themselves.

Werner Creutzfeldt served in many national and international positions, including as President of the European Association for the Study of Diabetes (1971–1974), President of the European Pancreatic Club (1969), President of the German Diabetes Association (1967–1968), and President of the German Association for Gastroenterology (1976–1977). He also was Editor-in-Chief of the journals “Diabetologia” (1973–1976) and “Digestion” (1978–1992).

During his most impressive career, Werner Creutzfeldt has received many honours including the Claude-Bernard-Medal of the European Association for the Study of Diabetes, the Ludwig-Heilmeyer-Medal of the German Association for Internal Medicine, the Paul-Langerhans-Medal of the German Diabetes Association, the Ismar-Boas-Medal and the Thannhauser-Medal of the German Gastroenterological Society and the most prestigious Ernst-Jung-Medal for Medicine in Gold of the Hamburg Ernst-Jung-Foundation.

With more than 700 published original articles, reviews and book chapters, Werner Creutzfeldt's scientific merits are too numerous to be described in detail. Perhaps the most important contributions made by the Göttingen research group directed and inspired by him include the characterisation of Gastric Inhibitory Polypeptide (GIP) in the physiology of postprandial glucose homeostasis, the uncovering of defects in the entero-insular axis in the pathophysiology of type 2 diabetes and the first description of the biological activity and antidiabetic effects of glucagon-like peptide-1 (GLP-1). In many ways, the development of dipeptidyl peptidase-4 (DPP-4) inhibitors and incretin mimetics as a novel concept in the pharmacotherapy of type 2 diabetes would be unthinkable without his fundamental contributions to the field.

Werner Creutzfeldt's broad range of interests not only covered several aspects of Gastroenterology and Endocrinology, but also questions of ethics in Medicine, the brutal abuse and misconduct of medical research by the nazi-regime in Germany, as well as the history of diabetes and gastrointestinal research. Having experienced the crimes of the nazi-regime as a young man (his mother was imprisoned by the nazis during the war), he actively fought against antisemitism and the discrimination of minorities throughout his life. As chairman of the Ethics Committee of the Medical Faculty of the University of Göttingen, he was a thoughtful and critical defender of the boundaries for medical research in human subjects.

It was Werner Creutzfeldt's vision that Gastroenterology, Endocrinology and Diabetology/Metabolism are one inseparable unit that should not be sub-divided into separate entities. He was one of the first scientists to realize the clinical importance of the gut as an endocrine organ and to uncover the close interaction between gastrointestinal motility, secretion and the regulation of energy balance. Today, his foresighted visions and ideas have become accepted doctrines in Internal Medicine, and his fundamental studies have paved the way towards new principles in our understanding of the pathophysiology and treatment of various diseases. Beside his research activities Werner Creutzfeldt was a brilliant physician who personally cared for his patients. His grand rounds on the ward were exceptional examples for his sophisticated clinical skills, his sharp intellect and his ability to dissect and analyse the clinical picture of a patient. One of this outstanding clinical lecture series was “Differential diagnosis in internal medicine” where he demonstrated that the physician should be able to deduce a diagnosis just from the patient's history and examination. This demonstration of the “Art of Medicine” excited his medical students who regularly overcrowded his lecture halls.

Wolfgang E. Schmidt
Juris J. Meier
(Excerpt from Regulatory Peptides, 137, 2006, 105-106)

Morton Grossman

Admin Octavo — 2008-05-20T09:03:33Z

Morton Grossman, the father of modern gastrointestinal endocrine physiology, was born in Massilon, Ohio in 1919. He attended Ohio State University where he received an undergraduate degree in biochemistry. He entered medical school at Ohio State University but subsequently transferred to Northwestern University where in 1944 he received both the M.D. and the Ph.D. degrees.

In 1946 Dr. Grossman received an appointment at the University of Illinois, and he was promoted to Professor of Clinical Science in 1952 at the age of 32.

From 1951 to 1955 he served as Head of the Physiology Branch of the Medical Nutrition Laboratory, first in Chicago, then at Fitzsimmons Army Hospital Base in Denver.

In 1955 Dr. Grossman became Chief of Gastroenterology at the Wadsworth VA Medical Center in Los Angeles.

From 1955 until 1962 he ran the section and trained clinical gastroenterologists, all the while continuing his research and publishing 50 papers. He was one of the first scientists appointed to the newly created Senior Medical Investigator program at the VA, a position which provided him the time and support needed to continue his research until his death. He was also Professor of Medicine and Physiology at the UCLA School of Medicine.

In 1973 Dr. Grossman learned that the National Institutes of Health intended to fund a center for the study of peptic ulcer disease. Almost single-handedly he organized the Wadsworth-UCLA and Dallas GI groups to submit a proposal which was funded.

Thus, in 1974 Dr. Grossman became the first Director of the Center for Ulcer Research and Education (CURE).

Dr. Grossman became involved with the journal Gastroenterology in 1943, served on its Editorial Board from 1957 to 1959, was Associate Editor from 1959 to 1960, Editor from 1960 to 1965, and Chairman of the Editorial Board from 1973 to 1978.

In 1979 he was presented the Friedenwald Medal from the American Gastroenterological Association.

In his life Dr. Grossman authored 400 articles, along with a similar number of book chapters and abstracts. He trained fellows from all parts of the world and from diverse backgrounds. Many of them today hold positions of distinction as heads of departments of gastroenterology, surgery, and physiology. His friends and colleagues will most remember his curiosity, his encyclopedic memory, the breadth of his interests and his energy in pursuing them, his intelligence, his perfectionism, his fairness, his wisdom, his integrity, his devotion, and his kindness.

His most important contributions lay in defining the secretory mechanisms of the stomach and pancreas and the actions of regulatory gastrointestinal peptides. He organized the first International Symposium of Gastrointestinal Hormone meeting in 1976, and guided and nurtured the society's biannual meetings as chair and member of the International Steering Committee. Beyond his own original contributions he synthesized much of the available knowledge in gastrointestinal physiology and endocrinology and set uncompromising standards for scientific validity and accuracy of reporting. He was truly one of the giants in gastrointestinal physiology of this century.

Vay Liang W. Go

Rod Gregory

Admin Octavo — 2008-05-20T09:00:44Z

Rod Gregory made fundamental contributions to the study of gut hormones through his isolation of the gastric acid stimulating hormone gastrin, the characterisation of its spectrum of actions, the identification of structure-activity relationships and discovery that gastrin was produced in excess in the tumours of patients with Zollinger-Ellison syndrome.

In the mid-1950s the existence of gastrin was regarded by many as not yet proven. At the time, Gregory together with his long standing co-worker Hilda Tracy was attempting to characterise the gastric acid inhibitory factor in urine known as urogastrone (this was later shown by Harry Gregory, no relation, to be epidermal growth factor).

Gregory and Tracy required a stable background of acid secretion against which to test preparations of urogastrone, and for various reasons the available acid secretagogues were unsatisfactory. They set out, therefore, to make preparations of gastrin and in due course this became their main interest. By the late 1950s new methods of column chromatography were becoming available (notably ion exchange media suitable for small acidic peptides, and gel filtration media such as Sephadex). Using these, and working on a large scale with the antral part of pig stomachs obtained from local abattoirs they quickly produced gastrin preparations that were far superior to any generated hitherto from which it became possible to obtain essentially homogenous peptide in suitable quantities for sequencing.

The sequence of two gastrins was subsequently determined in collaboration with George Kenner who was a distinguished peptide chemist in the University of Liverpool, Chemistry Department at the time. The peptides were shown to be identical heptadecapeptides differing in the presence or absence of a sulphate group on a solitary tyrosine.

Kenner's group then synthesised these peptides, and prepared many fragments and analogues which allowed the elucidation of structure-activity relationships including the crucial discovery that the C-terminal tetrapeptide amide was the minimal fragment with full biological activity. Shortly afterwards it became clear from the work of Viktor Mutt and Erik Jorpes on the intestinal hormone cholecystokinin, and that of Vittorio Erspamer on the amphibian skin peptide caerulein, that all three peptides shared an identical C-terminal pentapeptide amide and that this accounted for similarities in their biological properties.

Gregory and Tracy went on to show that the pure gastrins acted on a variety of different organs in addition to stimulation of acid secretion by the stomach, including stimulation of gastrointestinal motility, and weak stimulation of pancreatic secretion and gall bladder contraction. In due course they also identified other gastrins including peptides of 34-amino acid residues that are now known to be intermediates in the biosynthesis of the heptadecapeptides. Importantly, they also showed that gastrin could be isolated in large amounts from tumours of the Zollinger-Ellison syndrome and so providing a mechanistic link between these tumours and the acid hypersecretion that characterises the syndrome. They also made purified gastrin freely available to many researchers around the world which stimulated activity in the area including the subsequent development of radioimmunassays.

Rod Gregory was trained as a physiologist in the Department of Physiology at University College London in the early 1930s. He was introduced to gastrointestinal physiology in the laboratory of Andrew Ivy at Northwestern University, Illinois, where he obtained a PhD. His work on gastrin was carried out while he was Holt Professor of Physiology, and Head of Department, at the University of Liverpool (appointed in 1948) and while he had full teaching and administrative roles.

His qualities as a teacher influenced many generations of students including Professor Sir David Weatherall FRS, FMedSci (founder of the Institute of Molecular Medicine, University of Oxford) who recently noted that his own interests in medical research were stimulated by Rod Gregory “whose brilliant lectures were clearly from a man who was creating science as well as teaching it”.

Gregory's work has proved enduring because he was one of the first to see, and to show, that progress in regulatory physiology depended on a rigorous understanding of molecular mechanisms and that work on the gut hormones required the widespread availability of pure peptides of defined sequence.

Graham J. Dockray

Viktor Mutt

Admin Octavo — 2008-05-20T09:00:07Z

Viktor Mutt is probably the scientist who has single-handedly contributed the most to the development of gut endocrinology.

Viktor Mutt was born on December 29, 1923, in Tartu, the old Estonian university town. He spent ten years in New York between the world wars, where his father was consul-general for the Democratic Republic Estonia.
In 1943, after his return to Estonia, Viktor entered medical school. To avoid forced military service in the Soviet army, he fled, under dramatic circumstances, to Finland, worked illegally on a Finnish farm for nearly a year, and, eventually, at the end of World War II, he came to Stockholm where he obtained a job as technical assistant at the laboratory of Erik Jorpes, professor of medical biochemistry at the Karolinska Instituttet.

For the rest of his life Viktor Mutt stayed at this laboratory. After passing the Swedish highschool exam, he joined the medical school at Karolinska, became bachelor of medicine, and in 1959 he defended his thesis on the purification of secretin. In 1960 he became docent, in 1962 research fellow, and in 1970 associate professor and head of the laboratory. Eventually, in 1979, he obtained a full professorship in biochemistry in Stockholm. After his retirement in 1989, Viktor continued his research until the very day of his death on September 9, 1998.

Viktor devoted his life to purification and identification of hormonal peptides from the gut, initially together with Jorpes, later with a number of younger scientists from Sweden (Birgitta Werner (his wife), Staffan Magnusson, Hans Jörnvall, Åke Rökaeus) and from the rest of the world (Joel Adelson, John Brown, Sami Said, Wolfgang Schmidt, Kezhio Tatemoto, Monique Vagne and others).

The peptide hormones and neuropeptides identified in Viktor's laboratory illustrate the significance of his work:

secretins (of different lengths: 27, 28, 29 and 71 amino acids);
cholecystokinins (-33, -39 and –58);
vasoactive intestinal polypeptide (VIP);
peptide histidine-isoleucin and methionine (PHI and PHM);
gastric inhibitory polypeptide (GIP);
motilin; peptide tyrosine-tyrosine (PYY);
neuropeptide tyrosine (NPY);
galanin and several others.

A break-through was the method developed by Mutt and Tatemoto for identification of carboxyamidated peptides in tissue extracts. Carboxyamidation is a general characteristic of half the bioactive, regulatory peptides.

Viktor Mutt's research has not only put gut endocrinology and the neuropeptide part of neurobiology on firm scientific footing. With his generous supply of bioactive peptides to laboratories all over the world, his work became a decisive prerequisite for a multitude of studies in gastroenterology, endocrinology and neurobiology, as well as for several diagnostic tests of, for instance, exocrine pancreatic function and gastrinomas.

In his later years Viktor received several major European awards, and in the USA he received the William Beaumont and Morton Grossman lecture awards. Viktor Mutt was also for several years nominated for the Nobel Prize. In view of Viktor Mutt's unique contributions to science, the steering committee of the International Symposia on Regulatory Peptides in 1992 established a biannual lectureship to commemorate Viktor Mutt's name in future research of regulatory peptides.

Jens F. Rehfeld

Gut hormone/REGPEP symposia

Admin Octavo — 2008-05-20T08:57:25Z

1.	Asilomar	1976
2	Beito	1978
3.	Cambridge	1980
4.	Stockholm	1982
5.	Rochester	1984
6.	Vancouver	1986
7.	Shizuoka	1988
8.	Timmendorfer Strand	1990
9.	Leuven	1992
10.	Santa Barbara	1994
11.	Copenhagen	1996
12.	Mackinac Island	1998
13.	Cairns	2000
14.	Boston	2002
15.	Toulouse	2004
16.	Hakone	2006

Based on Creutzfeldt Scand J Clin Lab Invest 61 (suppl 234): 29-34, 2001

A symposium on Gastrointestinal Hormones was held at the University of Texas Medical Branch, Galveston, Texas, on 9-12 October 1974. 41 scientists from 10 countries presented papers.

Front Row: Makhlouf, Tract, Larsson, Grossman, Gregory, Thompson, Bodansvky, Chey, McGuigan, Cohen, Andersson
Second Row: Gardner, Solcia, Rayford, Adelson, Kelly, Lambert, Johnson, Go, Hansky, Erspamer, Boden

Third Row: Said, Debas, Unger, Creutzfeldt, Konturek, Barrowman, Jacobson, Becker, Schofield, Dockray, Straus, Meyer, Galardy, Brown, Olbe, Bloom, Rehfeld Not pictured: Yalow.